Ovarian cancer is a deadly malignant tumor that is difficult to detect early in the disease. The study of biomarkers is extremely important for the early diagnosis and treatment of ovarian cancer. As an expert in the field of biomarkers, Creative BioMart Biomarker has extensive experience in detecting various tumor-related biomarkers and can provide customers with fast and accurate test results. We provide customers with high-quality ovarian cancer-related biomarker detection services to meet customer research needs and help customers shorten the research cycle.
Like endometrial cancer and cervical cancer, ovarian cancer is a common malignant tumor in the female reproductive system and has a high mortality rate. Ovarian cancer is latent, and many patients have no symptoms early in the disease, and their first symptoms appear only in the later stages of the disease. Therefore, only a few patients can find the tumor early in the disease, and for most ovarian cancer patients, they are in the late stage of the tumor when they are diagnosed, which will increase the difficulty of treatment and lead to an increase in the mortality of ovarian cancer patients, and shorten the overall survival time. In addition, due to the spread of ovarian cancer, the disease may spread to tissues or organs other than the ovary at an advanced stage. Therefore, for ovarian cancer, its early detection is particularly important for its treatment. Transvaginal ultrasound (TVUS) is currently one of the main diagnostic methods for ovarian cancer, but it has defects in the diagnosis of ovarian cancer and cannot accurately distinguish between benign and malignant tumors. Tumor biomarkers not only play an important role in disease treatment response monitoring, prognosis analysis and disease risk assessment, but also bring new prospects to the early diagnosis of diseases. Detecting the level of cancer antigen 125 (CA-125) in the blood is one of the current diagnostic methods for ovarian cancer. CA-125 is a tumor biomarker commonly used for preoperative detection, which can help predict potential malignant tumors. However, CA-125 only showed elevated expression levels in about 50% of early patients, and CA-125 levels in serum were not specific to ovarian cancer. Some other factors may also cause elevated levels of CA-125, such as in benign ovarian diseases and nongynecologic conditions. Therefore, it is necessary to find and study some other biomarkers complementary to CA-125, which are used for early diagnosis of ovarian cancer and disease course monitoring.
Figure 1. Summary of epithelial ovarian cancer (EOC) biomarkers. (Muinao, et al. 2018)
Creative BioMart Biomarker provides high-quality detection services for ovarian cancer biomarkers that are applicable to a variety of biomarkers. If you do not find detection services for your research object on this webpage, you can find more biomarkers in biomarker menu or contact us to get more help. We have a technical team with rich experience in tumor biomarker detection, as well as multiple technical platforms suitable for biomarker detection, capable of accurate, specific and sensitive detection for various types of samples. If you are seeking ovarian cancer biomarker detection services, please feel free to contact us, we look forward to being your trusted partner.